Journal
BRITISH JOURNAL OF CANCER
Volume 124, Issue 10, Pages 1615-1617Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-020-01232-6
Keywords
-
Categories
Funding
- Francis Crick Institute from Cancer Research UK [FC001169]
- UK Medical Research Council [FC001169]
- Wellcome Trust [FC001169, 211179/Z/18/Z]
- Cancer Research UK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network)
- Cancer Research UK Lung Cancer Centre of Excellence
- Rosetrees Trust
- Butterfield Trust
- Stoneygate Trust
- NovoNordisk Foundation [ID16584]
- Royal Society Research Professorships Enhancement Award [RP/EA/180007]
- NIHR BRC at University College London Hospitals
- CRUK-UCL Centre
- Experimental Cancer Medicine Centre
- Breast Cancer Research Foundation (BCRF)
- Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant [SU2C-AACR-DT23-17]
- European Research Council (ERC) under the European Union's Seventh Framework Programme (FP7/20072013) Consolidator Grant (FP7-THESEUS) [617844]
- European Commission ITN (FP7PloidyNet) [607722]
- ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 research and innovation programme [835297]
- Chromavision from the European Union's Horizon 2020 research and innovation programme [665233]
- Royal Society [211179/Z/18/Z]
- Cancer Research UK
- Rosetrees
- CRUK University College London Experimental Cancer Medicine Centre
- Wellcome Trust [211179/Z/18/Z] Funding Source: Wellcome Trust
- European Research Council (ERC) [617844] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Understanding how tumors evolve and evade immune recognition is crucial for improving cancer immunotherapy and patient outcomes. Integration of multi-region genomic, transcriptomic, epigenomic, pathology, and clinical data is essential for systematic examination of immune escape mechanisms and implications for immunotherapy approaches.
Understanding how a tumour evolves and avoids immune recognition is paramount to improving cancer immunotherapy and patient outcome. Here we examine our recent integration of multi-region genomic, transcriptomic, epigenomic, pathology, and clinical data, highlight the need for a systematic examination of immune escape mechanisms, and discuss implications for immunotherapy approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
